Body composition changes during and after curative chemotherapy in patients with testicular cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F22%3A10418910" target="_blank" >RIV/00216208:11110/22:10418910 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/22:43920867 RIV/00064190:_____/21:N0000031

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=wH6otgRmnG" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=wH6otgRmnG</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2020.058" target="_blank" >10.5507/bp.2020.058</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Body composition changes during and after curative chemotherapy in patients with testicular cancer

Popis výsledku v původním jazyce

BACKGROUND: Testicular cancer is associated with excellent prognosis and cure is achieved in most patients with advanced cancer treated with cisplatin-based chemotherapy. However, testicular cancer survivors are at increased risk of accelerated atherosclerosis, which significantly contributes to their late morbidity and mortality. Atherosclerosis is associated with a higher proportion of fat mass and especially with increased amount of visceral fat. We explored the effects of cisplatin-based chemotherapy on body composition during and after the treatment. PATIENTS AND METHODS: We studied 30 testicular cancer patients before chemotherapy, after the second cycle of chemotherapy and three months after the end of chemotherapy. Body composition parameters were evaluated using bioelectrical impedance analysis (BIA). RESULTS: Three months after the end of chemotherapy the fat mass had increased from 22.04+-7.15% to 23.92+-7.33% (P=0.026) and visceral fat volume had increased by 17% from 2.36+-1.75l to 2.77+-1.94l (P=0.013). In the whole sample there was a decrease in muscle mass after the second cycle of chemotherapy (-1.33 +- 2 kg on average; P=0.005). The changes in body composition varied according to distinct baseline fat mass. CONCLUSION: Cisplatin-based chemotherapy was associated with increase of fat mass, visceral fat, and body mass index. We also observed decrease in muscle mass and total body water. Our results suggest that BIA could help to target preventative measures to avert the acceleration of atherosclerosis in patients treated with cisplatin-based chemotherapy.

Název v anglickém jazyce

Body composition changes during and after curative chemotherapy in patients with testicular cancer

Popis výsledku anglicky

BACKGROUND: Testicular cancer is associated with excellent prognosis and cure is achieved in most patients with advanced cancer treated with cisplatin-based chemotherapy. However, testicular cancer survivors are at increased risk of accelerated atherosclerosis, which significantly contributes to their late morbidity and mortality. Atherosclerosis is associated with a higher proportion of fat mass and especially with increased amount of visceral fat. We explored the effects of cisplatin-based chemotherapy on body composition during and after the treatment. PATIENTS AND METHODS: We studied 30 testicular cancer patients before chemotherapy, after the second cycle of chemotherapy and three months after the end of chemotherapy. Body composition parameters were evaluated using bioelectrical impedance analysis (BIA). RESULTS: Three months after the end of chemotherapy the fat mass had increased from 22.04+-7.15% to 23.92+-7.33% (P=0.026) and visceral fat volume had increased by 17% from 2.36+-1.75l to 2.77+-1.94l (P=0.013). In the whole sample there was a decrease in muscle mass after the second cycle of chemotherapy (-1.33 +- 2 kg on average; P=0.005). The changes in body composition varied according to distinct baseline fat mass. CONCLUSION: Cisplatin-based chemotherapy was associated with increase of fat mass, visceral fat, and body mass index. We also observed decrease in muscle mass and total body water. Our results suggest that BIA could help to target preventative measures to avert the acceleration of atherosclerosis in patients treated with cisplatin-based chemotherapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers

ISSN

1213-8118

e-ISSN

1804-7521

Svazek periodika

166

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

91-96

Kód UT WoS článku

000731342000001

EID výsledku v databázi Scopus

2-s2.0-85126490743